FDA Shortens Moderna COVID-19 Vaccine Booster Interval

Descovy Granted Expanded Pediatric Indication for HIV
January 7, 2022
Viona Pharmaceuticals Recalls Metformin Due to NDMA
January 7, 2022
Descovy Granted Expanded Pediatric Indication for HIV
January 7, 2022
Viona Pharmaceuticals Recalls Metformin Due to NDMA
January 7, 2022

January 7, 2022 – The U.S. FDA has updated emergency use authorization for Moderna's COVID-19 vaccine to shorten the time between the primary vaccination series and receipt of a booster dose.

  • Originally, the booster dose was authorized to be given six months following the completion of a primary vaccination series. It can now be given five months following primary vaccination.
  • Moderna's vaccine can be used to provide a booster dose after completing primary vaccination with the Janssen COVID-19 vaccine, the Moderna COVID-19 vaccine, or Pfizer’s Comirnaty. It is authorized for use in individuals who are at least 18 years old.